Literature DB >> 25979948

Inhibition of G9a methyltransferase stimulates fetal hemoglobin production by facilitating LCR/γ-globin looping.

Ivan Krivega1, Colleen Byrnes2, Jaira F de Vasconcellos2, Y Terry Lee2, Megha Kaushal2, Ann Dean1, Jeffery L Miller2.   

Abstract

Induction of fetal hemoglobin (HbF) production in adult erythrocytes can reduce the severity of sickle cell disease and β-thalassemia. Transcription of β-globin genes is regulated by the distant locus control region (LCR), which is brought into direct gene contact by the LDB1/GATA-1/TAL1/LMO2-containing complex. Inhibition of G9a H3K9 methyltransferase by the chemical compound UNC0638 activates fetal and represses adult β-globin gene expression in adult human hematopoietic precursor cells, but the underlying mechanisms are unclear. Here we studied UNC0638 effects on β-globin gene expression using ex vivo differentiation of CD34(+) erythroid progenitor cells from peripheral blood of healthy adult donors. UNC0638 inhibition of G9a caused dosed accumulation of HbF up to 30% of total hemoglobin in differentiated cells. Elevation of HbF was associated with significant activation of fetal γ-globin and repression of adult β-globin transcription. Changes in gene expression were associated with widespread loss of H3K9me2 in the locus and gain of LDB1 complex occupancy at the γ-globin promoters as well as de novo formation of LCR/γ-globin contacts. Our findings demonstrate that G9a establishes epigenetic conditions preventing activation of γ-globin genes during differentiation of adult erythroid progenitor cells. In this view, manipulation of G9a represents a promising epigenetic approach for treatment of β-hemoglobinopathies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25979948      PMCID: PMC4520881          DOI: 10.1182/blood-2015-02-629972

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Looping and interaction between hypersensitive sites in the active beta-globin locus.

Authors:  Bas Tolhuis; Robert Jan Palstra; Erik Splinter; Frank Grosveld; Wouter de Laat
Journal:  Mol Cell       Date:  2002-12       Impact factor: 17.970

2.  5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation.

Authors:  R J Wozniak; W T Klimecki; S S Lau; Y Feinstein; B W Futscher
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

3.  Effect of 5-aza-2'-deoxycytidine (Dacogen) on covalent histone modifications of chromatin associated with the epsilon-, gamma-, and beta-globin promoters in Papio anubis.

Authors:  Donald Lavelle; Kestis Vaitkus; Maria Hankewych; Mahipal Singh; Joseph DeSimone
Journal:  Exp Hematol       Date:  2006-03       Impact factor: 3.084

4.  Polycomb-dependent H3K27me1 and H3K27me2 regulate active transcription and enhancer fidelity.

Authors:  Karin J Ferrari; Andrea Scelfo; Sriganesh Jammula; Alessandro Cuomo; Iros Barozzi; Alexandra Stützer; Wolfgang Fischle; Tiziana Bonaldi; Diego Pasini
Journal:  Mol Cell       Date:  2013-11-27       Impact factor: 17.970

5.  The switch from fetal to adult hemoglobin.

Authors:  Vijay G Sankaran; Stuart H Orkin
Journal:  Cold Spring Harb Perspect Med       Date:  2013-01-01       Impact factor: 6.915

6.  Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.

Authors:  Feng Liu; Dalia Barsyte-Lovejoy; Fengling Li; Yan Xiong; Victoria Korboukh; Xi-Ping Huang; Abdellah Allali-Hassani; William P Janzen; Bryan L Roth; Stephen V Frye; Cheryl H Arrowsmith; Peter J Brown; Masoud Vedadi; Jian Jin
Journal:  J Med Chem       Date:  2013-10-31       Impact factor: 7.446

7.  Protein lysine methyltransferase G9a acts on non-histone targets.

Authors:  Philipp Rathert; Arunkumar Dhayalan; Marie Murakami; Xing Zhang; Raluca Tamas; Renata Jurkowska; Yasuhiko Komatsu; Yoichi Shinkai; Xiaodong Cheng; Albert Jeltsch
Journal:  Nat Chem Biol       Date:  2008-04-27       Impact factor: 15.040

8.  Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells.

Authors:  Toshihiko Tanno; Prashanth Porayette; Orapan Sripichai; Seung-Jae Noh; Colleen Byrnes; Ajoy Bhupatiraju; Y Terry Lee; Julia B Goodnough; Omid Harandi; Tomas Ganz; Robert F Paulson; Jeffery L Miller
Journal:  Blood       Date:  2009-05-04       Impact factor: 22.113

Review 9.  Update on fetal hemoglobin gene regulation in hemoglobinopathies.

Authors:  Daniel E Bauer; Stuart H Orkin
Journal:  Curr Opin Pediatr       Date:  2011-02       Impact factor: 2.856

10.  The hematopoietic regulator TAL1 is required for chromatin looping between the β-globin LCR and human γ-globin genes to activate transcription.

Authors:  Won Ju Yun; Yea Woon Kim; Yujin Kang; Jungbae Lee; Ann Dean; AeRi Kim
Journal:  Nucleic Acids Res       Date:  2014-01-26       Impact factor: 16.971

View more
  28 in total

1.  Pharmacologic control of chromatin looping.

Authors:  Marjorie Brand
Journal:  Blood       Date:  2015-07-30       Impact factor: 22.113

2.  EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression.

Authors:  Aline Renneville; Peter Van Galen; Matthew C Canver; Marie McConkey; John M Krill-Burger; David M Dorfman; Edward B Holson; Bradley E Bernstein; Stuart H Orkin; Daniel E Bauer; Benjamin L Ebert
Journal:  Blood       Date:  2015-08-28       Impact factor: 22.113

Review 3.  Fetal Hemoglobin Induction by Epigenetic Drugs.

Authors:  Donald Lavelle; James Douglas Engel; Yogen Saunthararajah
Journal:  Semin Hematol       Date:  2018-04-22       Impact factor: 3.851

Review 4.  Chromatin looping as a target for altering erythroid gene expression.

Authors:  Ivan Krivega; Ann Dean
Journal:  Ann N Y Acad Sci       Date:  2016-02-25       Impact factor: 5.691

Review 5.  New insights into sickle cell disease: mechanisms and investigational therapies.

Authors:  Gregory J Kato
Journal:  Curr Opin Hematol       Date:  2016-05       Impact factor: 3.284

Review 6.  Potential role of LSD1 inhibitors in the treatment of sickle cell disease: a review of preclinical animal model data.

Authors:  Angela Rivers; Ramasamy Jagadeeswaran; Donald Lavelle
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-08-01       Impact factor: 3.619

Review 7.  Customizing the genome as therapy for the β-hemoglobinopathies.

Authors:  Matthew C Canver; Stuart H Orkin
Journal:  Blood       Date:  2016-04-06       Impact factor: 22.113

8.  Epigenetic Medicinal Chemistry.

Authors:  Robert A Copeland
Journal:  ACS Med Chem Lett       Date:  2015-12-10       Impact factor: 4.345

Review 9.  Manipulation of Developmental Gamma-Globin Gene Expression: an Approach for Healing Hemoglobinopathies.

Authors:  Vigneshwaran Venkatesan; Saranya Srinivasan; Prathibha Babu; Saravanabhavan Thangavel
Journal:  Mol Cell Biol       Date:  2020-12-21       Impact factor: 4.272

Review 10.  Hemoglobin genetics: recent contributions of GWAS and gene editing.

Authors:  Elenoe C Smith; Stuart H Orkin
Journal:  Hum Mol Genet       Date:  2016-06-23       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.